Cardiac Xenograft Rejection Measurement Methods
Summary
The USPTO published patent application US20260091096A1 disclosing methods for measuring cardiac xenograft immune rejection progress. The application covers transgenic pig preparations with reduced glycan antigens (Sda/SDa-like and α-Gal) and recipient immunological response modifications targeting CD46, CD59, CD9, PROCR, and ANXA2. Inventors are Guerard W. Byrne and Christopher G.A. McGregor, with priority date September 15, 2025.
What changed
The patent application discloses methods and materials for reducing cardiac xenograft rejection including: (1) preparing transgenic pigs expressing reduced endogenous Sda or SDa-like glycans derived from the B4GALNT2 glycosyltransferase and/or reduced α-Gal antigens; (2) modifying xenograft recipient immunological responses to non-Gal antigens via CD46, CD59, CD9, PROCR, and ANXA2 expression; and (3) monitoring xenotransplant immunologic rejection progress.
Biotechnology companies, pharmaceutical firms, and research institutions developing xenotransplantation technologies should review the application claims for potential licensing opportunities or to assess freedom-to-operate. The publication establishes a priority date of September 15, 2025; patent prosecution may take several years before grant. No compliance deadlines or penalties are associated with this publication.
What to do next
- Review patent claims for relevance to xenotransplantation programs
- Assess freedom-to-operate for any overlapping research
- Evaluate potential licensing opportunities if developing similar transgenic pig or rejection monitoring methods
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MEASURING THE PROGRESS OF CARDIAC XENOGRAFT IMMUNE REJECTION
Application US20260091096A1 Kind: A1 Apr 02, 2026
Inventors
Guerard W. Byrne, Christopher G.A. McGregor
Abstract
This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.
CPC Classifications
A61K 39/001 A01K 67/0276 A61K 35/34 C12N 15/8509 A01K 2207/30 A01K 2227/108 A01K 2267/02 A01K 2267/025 A61K 38/00
Filing Date
2025-09-15
Application No.
19329042
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.